Reta Peptide (Retatrutide): How the Triple-Receptor GLP-1/GIP/Glucagon Agonist Works

Reta peptide is the informal nickname for retatrutide (LY-3437943), an investigational once-weekly injectable peptide from Eli Lilly that activates three metabolic hormone receptors — GLP-1, GIP, and glucagon. In a Phase 2 trial published in 2023, the highest studied dose produced approximately 24% mean body-weight loss at 48 weeks, alongside gastrointestinal side effects [1]. Retatrutide is currently in Phase 3 (TRIUMPH) trials and is not FDA-approved for any use [2][4]. Individual results vary, and 'research peptide' versions sold online are not regulated for human use [3].

What is reta peptide (retatrutide)?

Retatrutide — pronounced reh-tuh-TROO-tide — is an investigational synthetic peptide being studied by Eli Lilly for chronic weight management, type 2 diabetes mellitus (T2DM), and related metabolic conditions [1][2]. Patients and online communities have shortened the name to 'reta' or 'reta peptide,' but those are not official terms.

Why people call it the 'triple-G' peptide

Most GLP-1 medications target one receptor (semaglutide) or two (tirzepatide, which activates GLP-1 and GIP). Retatrutide is the first advanced-stage candidate to activate three: GLP-1, GIP, and glucagon receptors [1][5]. That triple action is why researchers and clinicians have nicknamed it the 'triple-G' or 'triple agonist' peptide.

Brand name, generic name, and development code

• Generic name: retatrutide
• Development code: LY-3437943
• Brand name: none — Eli Lilly has not announced a trade name because the drug is not approved
• Informal names: reta, reta peptide, triple-G

How does retatrutide work in the body?

Retatrutide mimics three natural hormones the gut and pancreas release after meals. By binding all three receptors, it has been studied for effects on appetite, blood sugar, fat storage, and resting energy expenditure [1][5]. Because retatrutide is investigational, all mechanism descriptions below come from trial data — not from real-world prescribing experience.

GLP-1 receptor: appetite and insulin

Glucagon-like peptide-1 (GLP-1) signaling reduces hunger, slows stomach emptying, and prompts the pancreas to release insulin when blood sugar rises. This is the same pathway used by semaglutide (Ozempic, Wegovy — a GLP-1 receptor agonist) [6]. Activating this pathway is also linked to the GI side effects discussed below.

GIP receptor: glucose and fat handling

Glucose-dependent insulinotropic polypeptide (GIP) helps insulin work more efficiently and may influence how fat tissue stores and releases energy. Activating GIP alongside GLP-1 is what made tirzepatide more effective than single-receptor drugs in head-to-head studies [5].

Glucagon receptor: energy expenditure and liver fat

Glucagon is best known for raising blood sugar, but it also increases energy expenditure and may reduce liver fat. Adding glucagon activity is the key difference between retatrutide and tirzepatide. In Phase 2 trials, this combination was associated with larger weight-loss numbers and meaningful reductions in liver fat — but also with small increases in resting heart rate and the same class-level GI side effects seen with other incretin drugs [1][7].

What do the clinical trials show?

All efficacy figures below come from clinical trials in selected participants. They do not predict what any individual would experience, and they are not a guarantee of outcome. Retatrutide remains investigational [4].

Phase 2 weight loss results

In a 48-week Phase 2 trial in adults with obesity published in the New England Journal of Medicine in 2023, retatrutide produced dose-dependent weight loss. At the highest studied dose (12 mg weekly), mean body-weight reduction was approximately 24.2%, with about a quarter of participants losing 30% or more of their starting weight [1]. Lower doses (1 mg, 4 mg, 8 mg) produced roughly 8–22% weight loss. Side effects in the same trial included nausea, vomiting, diarrhea, and constipation — most common during dose escalation [1]. Individual results vary.

TRIUMPH Phase 3 results in obesity and type 2 diabetes

The TRIUMPH Phase 3 program is testing retatrutide across obesity (TRIUMPH-1, -3, -4), type 2 diabetes (TRIUMPH-2), knee osteoarthritis with obesity, and cardiovascular outcomes [2]. Topline results communicated by Eli Lilly have reported weight loss in the same general range as Phase 2, along with improvements in HbA1c (a 3-month average of blood sugar) in participants with T2DM [2][7]. Full peer-reviewed Phase 3 publications are pending, and the drug remains investigational [4].

Effects on liver fat, knee osteoarthritis, and metabolic markers

Sub-studies of the Phase 2 program reported large reductions in liver fat content in people with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) — though retatrutide is being studied for, not approved to treat, this condition [7]. Trials in knee osteoarthritis with obesity are investigating whether weight loss translates into reduced joint pain. Retatrutide has also lowered blood pressure, triglycerides, and HbA1c in trial participants with diabetes, with the same GI side-effect profile [1][2].

How does retatrutide compare to tirzepatide and semaglutide?

All three are once-weekly injectable peptides, but they differ in how many receptors they target and how much weight loss they produced in their respective trials. Retatrutide has not been studied head-to-head against tirzepatide or semaglutide, so cross-trial numbers should be interpreted with caution [1][5][6]. Only tirzepatide and semaglutide are FDA-approved and clinically available today.

If you are weighing options that are actually available today, our deeper comparison of tirzepatide vs semaglutide walks through head-to-head trial data, side effects, and cost. For broader context on incretin side effects, see our GLP-1 side effects guide.

How is reta peptide taken in trials?

Weekly injection format

In clinical trials, retatrutide is given as a subcutaneous injection once per week, similar to semaglutide and tirzepatide [1]. Trial protocols administer it in the abdomen, thigh, or upper arm under research supervision.

Dose escalation in trials

Like other incretin medications studied to date, retatrutide is started at a low dose and gradually increased over several months to improve tolerability. Phase 2 doses studied included a range from low milligram amounts up to 12 mg weekly [1]. Because retatrutide is investigational and not FDA-approved, there is no approved dosing schedule, and this article does not provide dosing instructions. Any decision about retatrutide can only occur inside a registered clinical trial under the care of trial investigators [4].

What are the side effects of retatrutide?

All efficacy results above must be read alongside the side-effect profile below. Retatrutide is investigational, the long-term safety profile is not fully characterized, and the FDA has not approved a label that would summarize warnings and contraindications [1][4].

Common gastrointestinal effects

The most common side effects reported in Phase 2 trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation. These were mostly mild to moderate and most common during dose escalation [1]. The pattern mirrors what is seen with approved GLP-1 medications like semaglutide and tirzepatide [6][8].

Heart rate and other reported effects

Phase 2 trials reported small dose-dependent increases in resting heart rate that peaked around 24 weeks and then declined [1]. Other reported effects included fatigue and appetite reduction that some participants found uncomfortable. Whether long-term cardiovascular outcomes differ from approved incretin drugs is being studied in the TRIUMPH outcomes trial [2].

Class-level cautions for incretin therapies

Approved GLP-1-based medications carry class-level cautions, including a boxed warning about thyroid C-cell tumors seen in rodent studies, and risks of pancreatitis, gallbladder disease, and severe gastrointestinal symptoms [6][8]. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN-2), a history of pancreatitis, or who are pregnant or breastfeeding are typically excluded from these therapies. Because retatrutide acts on the same incretin pathways, similar cautions would likely apply if approved — but until the FDA reviews the data, the full contraindication list is not established [4].

Is retatrutide FDA-approved, and how can you access it?

Current regulatory status

Retatrutide is NOT FDA-approved for any use as of publication. Eli Lilly is running the Phase 3 TRIUMPH program, and a regulatory submission would only be possible after those trials conclude and are reviewed [2][4]. Until then, retatrutide cannot be legally prescribed in the United States outside of a registered clinical trial. We are not predicting an approval timeline; the FDA review process is independent.

Risks of unregulated 'research peptide' sellers

Vials labeled retatrutide are sold by overseas vendors as 'research peptides' or 'not for human use.' These products are not FDA-regulated, not tested for sterility or purity, and have been associated with contamination, mislabeled potency, and infection risk in published reports of unregulated peptide use [3]. Using them is not the same as receiving a compounded medication from a licensed 503A pharmacy under a valid prescription.

Clinician-reviewed paths to approved GLP-1 options today

If you are interested in the metabolic and weight-loss benefits the triple-G class is being studied for, the FDA-approved options available today are semaglutide (Wegovy, Ozempic — a GLP-1 receptor agonist) and tirzepatide (Zepbound, Mounjaro — a dual GLP-1/GIP receptor agonist) [6][8]. Both are also available as compounded semaglutide and compounded tirzepatide through licensed 503A pharmacies when clinically appropriate. Below is a plain-English snapshot of the telehealth paths patients commonly use to get a clinician evaluation — Chia is included as one option, alongside categories like large national telehealth brands and traditional in-person clinics.

Ways to get a clinician-reviewed GLP-1 evaluation

A licensed clinician — not an article — makes the final eligibility and prescribing decision. If you want to see the full patient-side workflow, our guide to getting a GLP-1 prescription walks through intake, labs, and follow-up.

Frequently asked questions

Keep reading

GLP-1 & Weight Loss

Retatrutide Cost in 2026: What to Expect and Why Prices Vary

Weight Loss

Peptides for Weight Loss: How They Work and What to Know

GLP-1 Weight Loss

Tirzepatide Dosing for Weight Loss: A Complete Guide to the Titration Schedule